Atlas Trials

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Clinical trial NCT02048709 · COMPLETED

Trial details

NCT number
NCT02048709
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumor
Start date
2014-04-01
Primary completion
2016-02-01
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.